Navigation Links
SCOLR Pharma, Inc. Reports Second Quarter 2009 Financial Results
Date:8/7/2009

General and administrative 972,884 1,062,646 2,126,535 2,294,930 ------- --------- --------- --------- Total operating expenses 1,805,855 2,451,014 3,888,023 4,804,202 --------- --------- --------- --------- Loss from operations (1,575,066) (2,171,443) (3,485,462) (4,259,076) Other income (expense) Interest income 2,040 59,353 11,112 159,671 Interest expense (1,082) (3,859) (3,512) (8,172) Other - 1,238 - 1,238 --- ----- --- ----- Total other income 958 56,732 7,600 152,737 --- ------ ----- ------- Net loss $(1,574,108)$(2,114,711)$(3,477,862)$(4,106,339) =========== =========== =========== =========== Net loss per share, basic and diluted $(0.04) $(0.05) $(0.08) $(0.10) ====== ====== ====== ====== Shares used in computing basic and diluted net loss per share 41,098,270 41,128,590 41,098,270 41,100,676 Contacts: Investor Relations: Cameron Associates Kevin McGrath 212.245.4577 Kevin@cameronassoc.com


'/>"/>
SOURCE SCOLR Pharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. SCOLR Pharma, Inc. Reports Fourth Quarter 2008 Financial Results
2. FDA Issues Complete Response Letter to SCOLR Pharmas Abbreviated New Drug Application for CDT(R) 12-Hour Pseudoephedrine
3. SCOLR Pharma, Inc. to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
4. SCOLR Pharma, Inc. Reports Second Quarter 2008 Financial Results
5. SCOLR Pharma, Inc. Schedules Second Quarter 2008 Financial Results Conference Call for August 7, 2008 at 11:30 A.M. Eastern
6. ULURU Discussions to Acquire York Pharma, plc Are Currently Terminated
7. CutisPharma, Inc. Receives Verified Accreditation for Wholesale Distributors from the National Association of Boards of Pharmacy for Woburn Facility
8. Strativas Development Partner, BioAlliance Pharma, Submits Loramyc(R) NDA
9. Evoke Pharma, Inc. Initiates Phase 2b Metoclopramide Intranasal Trial (MINT) in Patients With Diabetic Gastroparesis
10. Sinobiopharma, Inc. Appoints New Director of Marketing
11. Houlihan Smith Arranges Non-Control Equity Investment Into Sottera, Inc., dba NJOY, by Miri Pharma, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... /CNW/ - Sunovion Pharmaceuticals Canada Inc. (Sunovion) today announced ... for use as a once-daily adjunctive therapy for the ... are not satisfactorily controlled with conventional therapy.  APTIOM TM ... 18 years of age. Epilepsy is ... to Epilepsy Canada, it affects 0.6% of the population ...
(Date:7/10/2014)... Product and process impurities in ... and are often “lost in the noise,” making ... presenters Dr. Rowel Tobias, Senior Scientist, Protein Chemistry ... of Quality at Nanotherapeutics, Inc., to lear about ... detection and quantitation while achieving the required specificity ...
(Date:7/10/2014)... (PRWEB) July 10, 2014 Unraveling life’s ... together. The Archer Family purchased a DNA ... DNA, but ended up with a lifetime of memories, ... within the family members’ DNA genuinely brought the family ... to search deeper into genetic history and prior to ...
(Date:7/10/2014)... Calabasas, CA (PRWEB) July 10, 2014 ... academic institutions and professional associations, addressed the challenges of ... & Medical Device Industries” through strategic sourcing. Describing the ... ) with the Supply Chain Management Institute ( SCMI) ... the event on June 24 at the Kroc Institute ...
Breaking Biology Technology:Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 3Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 4Novel Ms Techniques Speed Detection of Biopharmaceutical Product and Process Impurities, New Webinar Hosted by Xtalks 2Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 2Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 3Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 4Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 5Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 2Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 3Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 4
... TherapySAN FRANCISCO, May 21 Gualberto Ruano, M.D., ... Research at Hartford Hospital and Simon Kung, M.D., ... will co-chair a symposium, " Emerging Clinical Applications ... the annual meeting of the American Psychiatric Association. ...
... AMSTERDAM, May 21 ,Agendia, a world leader in molecular ... University of California San Francisco ,and the Netherlands ... American Society of Clinical Oncology Annual Meeting, May 29 ... The study results further underpin the broad ...
... Sky One Medical,Inc. ("China Sky One Medical" or ... leading,fully integrated pharmaceutical company in the People,s Republic ... agreement with Taiwan Golden,Biotechnology Corporation to begin cooperating ... Antroquinonol. , Golden Biotechnology ...
Cached Biology Technology:Genomas and Institute of Living Among Organizers of Pharmacogenetics Symposium at 2009 Annual Meeting of the American Psychiatric Association 2Agendia to Present Multiple Predictive and Prognostic Studies on Breast and Colorectal Cancers at ASCO Annual Meeting 2Agendia to Present Multiple Predictive and Prognostic Studies on Breast and Colorectal Cancers at ASCO Annual Meeting 3China Sky One Medical, Inc. Signs Agreement with Taiwan Golden Biotechnology Corp. on Development of New Anti-Cancer Drug 2China Sky One Medical, Inc. Signs Agreement with Taiwan Golden Biotechnology Corp. on Development of New Anti-Cancer Drug 3
(Date:7/11/2014)... is creating a new professorship in tissue engineering ... for Molecular Engineering and the Marine Biological Laboratory, ... Millicent and Eugene Bell Foundation., The Eugene Bell ... Institute for Molecular Engineering. That endowed chair holder ... MBL,s Eugene Bell Center for Regenerative Biology and ...
(Date:7/11/2014)... 3, 2014, Shenzhen, China Researchers from Salk Institute ... the first time evaluated the safety and reliability ... successfully developed a new method, TALEN-HDAdV, which could ... stem cell (hiPSC). This study published online in ... theoretical foundation for stem cell-based gene therapy. , ...
(Date:7/11/2014)... 2014 The increased risk of kidney injury related ... fluids reflects the mass of HES molecules, according to ... journal of the International Anesthesia Research Society (IARS). , ... effect of HES on cultured human renal proximal tubule ... Wunder and colleagues of University Hospital Wrzburg, Austria. ...
Breaking Biology News(10 mins):New professorship in tissue engineering links molecular engineering, marine biology 2A new genome editing method brings the possibility of gene therapies closer to reality 2In lab studies, hydroxyethyl starch has direct harmful effects on kidney cells 2
... at Washington University in St. Louis is giving the ... more clues about our biological clock. , VIP is ... a neuropeptide originally found in the gut, that is ... the brain. , Erik Herzog, Ph.D., Washington University assistant ...
... appreciated as a disease of the genes, cancer is ... regulation. Scientists have identified some of the first genetic ... tumor suppressor genes. Full-blown tumors and metastatic cancers, however, ... given tumor. An important scientific question, and one with ...
... an Australian first, UNSW researchers have developed three clones of ... lead to new treatments for diabetes, Parkinson's disease and spinal ... technique, which is a very accurate way of extracting and ... Kuldip Sidhu, who is leading the research and is based ...
Cached Biology News:Discovery clarifies role of peptide in biological clock 2Unchecked DNA replication drives earliest steps toward cancer 2Unchecked DNA replication drives earliest steps toward cancer 3Stem cell research - new cell lines 2
... Well Plate Sterile with ... range of 384-well plates ... screening and research. These ... and are suitable for ...
Request Info...
... to Cytokeratin 5 / 6 Cytokeratin ... weight, basic type of cytokeratin expressed in ... layers of stratified epithelia as well as ... cells and mesothelioma. Cytokeratin 6 (56 kD) ...
Bovine Coronary Artery Endothelial Cells (BCAEC) (>500,000 cells)...
Biology Products: